ID   LCK_HUMAN               Reviewed;         509 AA.
AC   P06239; D3DPP8; P07100; Q12850; Q13152; Q5TDH8; Q5TDH9; Q7RTZ3;
AC   Q96DW4; Q9NYT8;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 6.
DT   10-MAY-2017, entry version 230.
DE   RecName: Full=Tyrosine-protein kinase Lck;
DE            EC=2.7.10.2;
DE   AltName: Full=Leukocyte C-terminal Src kinase;
DE            Short=LSK;
DE   AltName: Full=Lymphocyte cell-specific protein-tyrosine kinase;
DE   AltName: Full=Protein YT16;
DE   AltName: Full=Proto-oncogene Lck;
DE   AltName: Full=T cell-specific protein-tyrosine kinase;
DE   AltName: Full=p56-LCK;
GN   Name=LCK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3493153; DOI=10.1002/eji.1830161229;
RA   Koga Y., Caccia N., Toyonaga B., Spolski R., Yanagi Y., Yoshikai Y.,
RA   Mak T.W.;
RT   "A human T cell-specific cDNA clone (YT16) encodes a protein with
RT   extensive homology to a family of protein-tyrosine kinases.";
RL   Eur. J. Immunol. 16:1643-1646(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3265417; DOI=10.1002/jcb.240380206;
RA   Perlmutter R.M., Marth J.D., Lewis D.B., Peet R., Ziegler S.F.,
RA   Wilson C.B.;
RT   "Structure and expression of lck transcripts in human lymphoid
RT   cells.";
RL   J. Cell. Biochem. 38:117-126(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2558056; DOI=10.1016/0378-1119(89)90144-3;
RA   Rouer E., van Huynh T., de Souza S.L., Lang M.C., Fischer S.,
RA   Benarous R.;
RT   "Structure of the human lck gene: differences in genomic organisation
RT   within src-related genes affect only N-terminal exons.";
RL   Gene 84:105-113(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS LEU-28; GLN-LYS-PRO-232 INS;
RP   VAL-353 AND LEU-447, AND PHOSPHORYLATION AT TYR-394 AND TYR-505.
RC   TISSUE=Leukemia;
RX   PubMed=8139546; DOI=10.1128/MCB.14.4.2429;
RA   Wright D.D., Sefton B.M., Kamps M.P.;
RT   "Oncogenic activation of the Lck protein accompanies translocation of
RT   the LCK gene in the human HSB2 T-cell leukemia.";
RL   Mol. Cell. Biol. 14:2429-2437(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND ALTERNATIVE SPLICING.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=7495859; DOI=10.1016/0167-4781(95)00162-A;
RA   Vogel L.B., Arthur R., Fujita D.J.;
RT   "An aberrant lck mRNA in two human T-cell lines.";
RL   Biochim. Biophys. Acta 1264:168-172(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12401726; DOI=10.2337/diabetes.51.11.3326;
RA   Nervi S., Nicodeme S., Gartioux C., Atlan C., Lathrop M., Reviron D.,
RA   Naquet P., Matsuda F., Imbert J., Vialettes B.;
RT   "No association between lck gene polymorphisms and protein level in
RT   type 1 diabetes.";
RL   Diabetes 51:3326-3330(2002).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-35.
RX   PubMed=2850479; DOI=10.1128/MCB.8.8.3058;
RA   Garvin A.M., Pawar S., Marth J.D., Perlmutter R.M.;
RT   "Structure of the murine lck gene and its rearrangement in a murine
RT   lymphoma cell line.";
RL   Mol. Cell. Biol. 8:3058-3064(1988).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-35.
RX   PubMed=2787474; DOI=10.1128/MCB.9.5.2173;
RA   Takadera T., Leung S., Gernone A., Koga Y., Takihara Y.,
RA   Miyamoto N.G., Mak T.W.;
RT   "Structure of the two promoters of the human lck gene: differential
RT   accumulation of two classes of lck transcripts in T cells.";
RL   Mol. Cell. Biol. 9:2173-2180(1989).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 14-509.
RC   TISSUE=Peripheral blood lymphocyte;
RX   PubMed=11009097;
RX   DOI=10.1002/1521-4141(200009)30:9<2632::AID-IMMU2632>3.0.CO;2-C;
RA   Boncristiano M., Majolini M.B., D'Elios M.M., Pacini S., Valensin S.,
RA   Ulivieri C., Amedei A., Falini B., Del Prete G., Telford J.L.,
RA   Baldari C.T.;
RT   "Defective recruitment and activation of ZAP-70 in common variable
RT   immunodeficiency patients with T cell defects.";
RL   Eur. J. Immunol. 30:2632-2638(2000).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 368-509.
RX   PubMed=2835736;
RA   Veillette A., Foss F.M., Sausville E.A., Bolen J.B., Rosen N.;
RT   "Expression of the lck tyrosine kinase gene in human colon carcinoma
RT   and other non-lymphoid human tumor cell lines.";
RL   Oncogene Res. 1:357-374(1987).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 375-509.
RX   PubMed=3489486; DOI=10.1016/0167-4889(86)90228-4;
RA   Trevillyan J.M., Lin Y., Chen S.J., Phillips C.A., Canna C.,
RA   Linna T.J.;
RT   "Human T lymphocytes express a protein-tyrosine kinase homologous to
RT   p56LSTRA.";
RL   Biochim. Biophys. Acta 888:286-295(1986).
RN   [15]
RP   PHOSPHORYLATION AT TYR-505.
RX   PubMed=1639064;
RA   Bergman M., Mustelin T., Oetken C., Partanen J., Flint N.A.,
RA   Amrein K.E., Autero M., Burn P., Alitalo K.;
RT   "The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and
RT   down regulates its catalytic activity.";
RL   EMBO J. 11:2919-2924(1992).
RN   [16]
RP   INTERACTION WITH PI3K.
RX   PubMed=7504174; DOI=10.1128/MCB.13.12.7408;
RA   Vogel L.B., Fujita D.J.;
RT   "The SH3 domain of p56lck is involved in binding to
RT   phosphatidylinositol 3'-kinase from T lymphocytes.";
RL   Mol. Cell. Biol. 13:7408-7417(1993).
RN   [17]
RP   INTERACTION WITH KHDRBS1.
RX   PubMed=7852312; DOI=10.1074/jbc.270.6.2506;
RA   Vogel L.B., Fujita D.J.;
RT   "p70 phosphorylation and binding to p56lck is an early event in
RT   interleukin-2-induced onset of cell cycle progression in T-
RT   lymphocytes.";
RL   J. Biol. Chem. 270:2506-2511(1995).
RN   [18]
RP   INTERACTION WITH SQSTM1, AND MUTAGENESIS OF SER-59 AND ARG-154.
RX   PubMed=8618896; DOI=10.1073/pnas.92.26.12338;
RA   Park I., Chung J., Walsh C.T., Yun Y., Strominger J.L., Shin J.;
RT   "Phosphotyrosine-independent binding of a 62-kDa protein to the src
RT   homology 2 (SH2) domain of p56lck and its regulation by
RT   phosphorylation of Ser-59 in the lck unique N-terminal region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:12338-12342(1995).
RN   [19]
RP   PHOSPHORYLATION AT TYR-505 BY CSK, AND AUTOPHOSPHORYLATION.
RX   PubMed=8631775; DOI=10.1074/jbc.271.13.7465;
RA   Bougeret C., Delaunay T., Romero F., Jullien P., Sabe H., Hanafusa H.,
RA   Benarous R., Fischer S.;
RT   "Detection of a physical and functional interaction between Csk and
RT   Lck which involves the SH2 domain of Csk and is mediated by
RT   autophosphorylation of Lck on tyrosine 394.";
RL   J. Biol. Chem. 271:7465-7472(1996).
RN   [20]
RP   INTERACTION WITH HIV-1 NEF.
RX   PubMed=8794306;
RA   Greenway A.L., Azad A., Mills J., McPhee D.A.;
RT   "Human immunodeficiency virus type 1 Nef binds directly to LCK and
RT   mitogen-activated protein kinase, inhibiting kinase activity.";
RL   J. Virol. 70:6701-6708(1996).
RN   [21]
RP   INTERACTION WITH AXL.
RX   PubMed=9178760; DOI=10.1038/sj.onc.1201123;
RA   Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R.,
RA   Ullrich A., Bartram C.R., Janssen J.W.;
RT   "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is
RT   mediated mainly by a multi-substrate docking-site.";
RL   Oncogene 14:2619-2631(1997).
RN   [22]
RP   REVIEW.
RX   PubMed=10848956; DOI=10.1046/j.1432-1327.2000.01412.x;
RA   Isakov N., Biesinger B.;
RT   "Lck protein tyrosine kinase is a key regulator of T-cell activation
RT   and a target for signal intervention by Herpesvirus saimiri and other
RT   viral gene products.";
RL   Eur. J. Biochem. 267:3413-3421(2000).
RN   [23]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12218089; DOI=10.4049/jimmunol.169.6.2813;
RA   Yasuda K., Nagafuku M., Shima T., Okada M., Yagi T., Yamada T.,
RA   Minaki Y., Kato A., Tani-Ichi S., Hamaoka T., Kosugi A.;
RT   "Fyn is essential for tyrosine phosphorylation of Csk-binding
RT   protein/phosphoprotein associated with glycolipid-enriched
RT   microdomains in lipid rafts in resting T cells.";
RL   J. Immunol. 169:2813-2817(2002).
RN   [24]
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RX   PubMed=11840567;
RX   DOI=10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H;
RA   Harris R.A., Yang A., Stein R.C., Lucy K., Brusten L., Herath A.,
RA   Parekh R., Waterfield M.D., O'Hare M.J., Neville M.A., Page M.J.,
RA   Zvelebil M.J.;
RT   "Cluster analysis of an extensive human breast cancer cell line
RT   protein expression map database.";
RL   Proteomics 2:212-223(2002).
RN   [25]
RP   INTERACTION WITH LIME1.
RX   PubMed=14610046; DOI=10.1084/jem.20031484;
RA   Brdickova N., Brdicka T., Angelisova P., Horvath O., Spicka J.,
RA   Hilgert I., Paces J., Simeoni L., Kliche S., Merten C., Schraven B.,
RA   Horejsi V.;
RT   "LIME: a new membrane raft-associated adaptor protein involved in CD4
RT   and CD8 coreceptor signaling.";
RL   J. Exp. Med. 198:1453-1462(2003).
RN   [26]
RP   INTERACTION WITH LIME1.
RX   PubMed=14610044; DOI=10.1084/jem.20030232;
RA   Hur E.M., Son M., Lee O.-H., Choi Y.B., Park C., Lee H., Yun Y.;
RT   "LIME, a novel transmembrane adaptor protein, associates with p56lck
RT   and mediates T cell activation.";
RL   J. Exp. Med. 198:1463-1473(2003).
RN   [27]
RP   INTERACTION WITH PTPRH.
RX   PubMed=12837766; DOI=10.1074/jbc.M300648200;
RA   Ito T., Okazawa H., Maruyama K., Tomizawa K., Motegi S., Ohnishi H.,
RA   Kuwano H., Kosugi A., Matozaki T.;
RT   "Interaction of SAP-1, a transmembrane-type protein-tyrosine
RT   phosphatase, with the tyrosine kinase Lck. Roles in regulation of T
RT   cell function.";
RL   J. Biol. Chem. 278:34854-34863(2003).
RN   [28]
RP   INTERACTION WITH UNC119.
RX   PubMed=14757743; DOI=10.1084/jem.20030589;
RA   Gorska M.M., Stafford S.J., Cen O., Sur S., Alam R.;
RT   "Unc119, a novel activator of Lck/Fyn, is essential for T cell
RT   activation.";
RL   J. Exp. Med. 199:369-379(2004).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF ZAP70.
RX   PubMed=16339550; DOI=10.4049/jimmunol.175.12.8123;
RA   Gelkop S., Gish G.D., Babichev Y., Pawson T., Isakov N.;
RT   "T cell activation-induced CrkII binding to the Zap70 protein tyrosine
RT   kinase is mediated by Lck-dependent phosphorylation of Zap70 tyrosine
RT   315.";
RL   J. Immunol. 175:8123-8132(2005).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [31]
RP   DEPHOSPHORYLATION BY PTN22.
RX   PubMed=16461343; DOI=10.1074/jbc.M600498200;
RA   Wu J., Katrekar A., Honigberg L.A., Smith A.M., Conn M.T., Tang J.,
RA   Jeffery D., Mortara K., Sampang J., Williams S.R., Buggy J.,
RA   Clark J.M.;
RT   "Identification of substrates of human protein-tyrosine phosphatase
RT   PTPN22.";
RL   J. Biol. Chem. 281:11002-11010(2006).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF TYROBP.
RX   PubMed=16709819; DOI=10.4049/jimmunol.176.11.6615;
RA   Mason L.H., Willette-Brown J., Taylor L.S., McVicar D.W.;
RT   "Regulation of Ly49D/DAP12 signal transduction by Src-family kinases
RT   and CD45.";
RL   J. Immunol. 176:6615-6623(2006).
RN   [33]
RP   INTERACTION WITH EPHA1; PTK2B AND PI3-KINASE.
RX   PubMed=17634955; DOI=10.1002/eji.200737111;
RA   Hjorthaug H.S., Aasheim H.C.;
RT   "Ephrin-A1 stimulates migration of CD8+CCR7+ T lymphocytes.";
RL   Eur. J. Immunol. 37:2326-2336(2007).
RN   [34]
RP   INTERACTION WITH CEACAM1.
RX   PubMed=18424730; DOI=10.4049/jimmunol.180.9.6085;
RA   Chen Z., Chen L., Qiao S.W., Nagaishi T., Blumberg R.S.;
RT   "Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits
RT   proximal TCR signaling by targeting ZAP-70.";
RL   J. Immunol. 180:6085-6093(2008).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-102; THR-159; SER-162;
RP   SER-194 AND TYR-505, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [38]
RP   FUNCTION IN PHOSPHORYLATION OF RUNX3.
RX   PubMed=20100835; DOI=10.1074/jbc.M109.071381;
RA   Goh Y.M., Cinghu S., Hong E.T., Lee Y.S., Kim J.H., Jang J.W.,
RA   Li Y.H., Chi X.Z., Lee K.S., Wee H., Ito Y., Oh B.C., Bae S.C.;
RT   "Src kinase phosphorylates RUNX3 at tyrosine residues and localizes
RT   the protein in the cytoplasm.";
RL   J. Biol. Chem. 285:10122-10129(2010).
RN   [39]
RP   FUNCTION IN PTK2B/PYK2 PHOSPHORYLATION.
RX   PubMed=20028775; DOI=10.1189/jlb.0409227;
RA   Collins M., Tremblay M., Chapman N., Curtiss M., Rothman P.B.,
RA   Houtman J.C.;
RT   "The T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402
RT   and 580 occurs via a distinct mechanism than other receptor systems.";
RL   J. Leukoc. Biol. 87:691-701(2010).
RN   [40]
RP   FUNCTION IN PHOSPHORYLATION OF RHOH.
RX   PubMed=20851766; DOI=10.1016/j.cellsig.2010.09.009;
RA   Wang H., Zeng X., Fan Z., Lim B.;
RT   "RhoH modulates pre-TCR and TCR signalling by regulating LCK.";
RL   Cell. Signal. 23:249-258(2011).
RN   [41]
RP   FUNCTION IN TCR SIGNALING, PHOSPHORYLATION, AND DEPHOSPHORYLATION AT
RP   TYR-394 BY PTPN2.
RX   PubMed=22080863; DOI=10.1172/JCI59492;
RA   Wiede F., Shields B.J., Chew S.H., Kyparissoudis K., van Vliet C.,
RA   Galic S., Tremblay M.L., Russell S.M., Godfrey D.I., Tiganis T.;
RT   "T cell protein tyrosine phosphatase attenuates T cell signaling to
RT   maintain tolerance in mice.";
RL   J. Clin. Invest. 121:4758-4774(2011).
RN   [42]
RP   FUNCTION IN PHOSPHORYLATION OF MAPT.
RX   PubMed=21269457; DOI=10.1186/1750-1326-6-12;
RA   Scales T.M., Derkinderen P., Leung K.Y., Byers H.L., Ward M.A.,
RA   Price C., Bird I.N., Perera T., Kellie S., Williamson R.,
RA   Anderton B.H., Reynolds C.H.;
RT   "Tyrosine phosphorylation of tau by the SRC family kinases lck and
RT   fyn.";
RL   Mol. Neurodegener. 6:12-12(2011).
RN   [43]
RP   ENZYME REGULATION.
RX   PubMed=21917715; DOI=10.1126/scisignal.2001893;
RA   Schoenborn J.R., Tan Y.X., Zhang C., Shokat K.M., Weiss A.;
RT   "Feedback circuits monitor and adjust Basal lck-dependent events in T
RT   cell receptor signaling.";
RL   Sci. Signal. 4:RA59-RA59(2011).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [45]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 UL46.
RX   PubMed=23946459; DOI=10.1128/JVI.01702-13;
RA   Strunk U., Saffran H.A., Wu F.W., Smiley J.R.;
RT   "Role of herpes simplex virus VP11/12 tyrosine-based motifs in binding
RT   and activation of the Src family kinase Lck and recruitment of p85,
RT   Grb2, and Shc.";
RL   J. Virol. 87:11276-11286(2013).
RN   [46]
RP   INTERACTION WITH ARAP AND FYB.
RX   PubMed=27335501; DOI=10.4049/jimmunol.1501913;
RA   Jung S.H., Yoo E.H., Yu M.J., Song H.M., Kang H.Y., Cho J.Y.,
RA   Lee J.R.;
RT   "ARAP, a novel adaptor protein, is required for TCR signaling and
RT   integrin-mediated adhesion.";
RL   J. Immunol. 197:942-952(2016).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 53-226.
RX   PubMed=7512222; DOI=10.1038/368764a0;
RA   Eck M.J., Atweell S.K., Shoelson S.E., Harrison S.C.;
RT   "Structure of the regulatory domains of the Src-family tyrosine kinase
RT   Lck.";
RL   Nature 368:764-769(1994).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 127-221.
RX   PubMed=7532720; DOI=10.1006/jmbi.1994.0089;
RA   Mikol V., Baumann G., Keller T.H., Manning U.M., Zurini M.G.M.;
RT   "The crystal structures of the SH2 domain of p56lck complexed with two
RT   phosphonopeptides suggest a gated peptide binding site.";
RL   J. Mol. Biol. 246:344-355(1995).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.0 ANGSTROMS) OF 122-226.
RX   PubMed=8604142; DOI=10.1006/jmbi.1996.0112;
RA   Tong L., Warren T.C., King J., Betageri R., Rose J., Jakes S.;
RT   "Crystal structures of the human p56lck SH2 domain in complex with two
RT   short phosphotyrosyl peptides at 1.0-A and 1.8-A resolution.";
RL   J. Mol. Biol. 256:601-610(1996).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 231-501.
RX   PubMed=8945479; DOI=10.1038/384484a0;
RA   Yamaguchi H., Hendrickson W.A.;
RT   "Structural basis for activation of human lymphocyte kinase Lck upon
RT   tyrosine phosphorylation.";
RL   Nature 384:484-489(1996).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 119-226.
RX   PubMed=9685372; DOI=10.1074/jbc.273.32.20238;
RA   Tong L., Warren T.C., Lukas S., Schembri-King J., Betageri R.,
RA   Proudfoot J.R., Jakes S.;
RT   "Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in
RT   SH2 domain binding.";
RL   J. Biol. Chem. 273:20238-20242(1998).
RN   [52]
RP   VARIANT IMD22 PRO-341.
RX   PubMed=22985903; DOI=10.1016/j.jaci.2012.07.029;
RA   Hauck F., Randriamampita C., Martin E., Gerart S., Lambert N., Lim A.,
RA   Soulier J., Maciorowski Z., Touzot F., Moshous D., Quartier P.,
RA   Heritier S., Blanche S., Rieux-Laucat F., Brousse N., Callebaut I.,
RA   Veillette A., Hivroz C., Fischer A., Latour S., Picard C.;
RT   "Primary T-cell immunodeficiency with immunodysregulation caused by
RT   autosomal recessive LCK deficiency.";
RL   J. Allergy Clin. Immunol. 130:1144-1152(2012).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that plays an
CC       essential role in the selection and maturation of developing T-
CC       cells in the thymus and in the function of mature T-cells. Plays a
CC       key role in T-cell antigen receptor (TCR)-linked signal
CC       transduction pathways. Constitutively associated with the
CC       cytoplasmic portions of the CD4 and CD8 surface receptors.
CC       Association of the TCR with a peptide antigen-bound MHC complex
CC       facilitates the interaction of CD4 and CD8 with MHC class II and
CC       class I molecules, respectively, thereby recruiting the associated
CC       LCK protein to the vicinity of the TCR/CD3 complex. LCK then
CC       phosphorylates tyrosine residues within the immunoreceptor
CC       tyrosine-based activation motifs (ITAM) of the cytoplasmic tails
CC       of the TCR-gamma chains and CD3 subunits, initiating the TCR/CD3
CC       signaling pathway. Once stimulated, the TCR recruits the tyrosine
CC       kinase ZAP70, that becomes phosphorylated and activated by LCK.
CC       Following this, a large number of signaling molecules are
CC       recruited, ultimately leading to lymphokine production. LCK also
CC       contributes to signaling by other receptor molecules. Associates
CC       directly with the cytoplasmic tail of CD2, which leads to
CC       hyperphosphorylation and activation of LCK. Also plays a role in
CC       the IL2 receptor-linked signaling pathway that controls the T-cell
CC       proliferative response. Binding of IL2 to its receptor results in
CC       increased activity of LCK. Is expressed at all stages of thymocyte
CC       development and is required for the regulation of maturation
CC       events that are governed by both pre-TCR and mature alpha beta
CC       TCR. Phosphorylates other substrates including RUNX3, PTK2B/PYK2,
CC       the microtubule-associated protein MAPT, RHOH or TYROBP. Interacts
CC       with ARAP (PubMed:27335501). {ECO:0000269|PubMed:16339550,
CC       ECO:0000269|PubMed:16709819, ECO:0000269|PubMed:20028775,
CC       ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20851766,
CC       ECO:0000269|PubMed:21269457, ECO:0000269|PubMed:22080863,
CC       ECO:0000269|PubMed:27335501}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: The relative activities of the inhibitory
CC       tyrosine-protein kinase CSK and the activating tyrosine-protein
CC       phosphatase PTPRC/CD45 determine the level of LCK activity. These
CC       interactions allow rapid and efficient activation of LCK in
CC       response to TCR stimulation. {ECO:0000269|PubMed:21917715}.
CC   -!- SUBUNIT: Binds to the cytoplasmic domain of cell surface
CC       receptors, such as AXL, CD2, CD4, CD5, CD8, CD44, CD45 and CD122.
CC       Also binds to effector molecules, such as PI4K, VAV1, RASA1, FYB
CC       and to other protein kinases including CDK1, RAF1, ZAP70 and SYK.
CC       Binds to phosphatidylinositol 3'-kinase (PI3K) from T-lymphocytes
CC       through its SH3 domain and to the tyrosine phosphorylated form of
CC       KHDRBS1/p70 through its SH2 domain. Binds to HIV-1 Nef through its
CC       SH3 domain. This interaction inhibits its tyrosine-kinase
CC       activity. Interacts with herpes simplex virus 1 UL46; this
CC       interaction activates LCK. Interacts with SQSTM1. Interacts with
CC       phosphorylated LIME1. Interacts with CBLB and PTPRH. Interacts
CC       with RUNX3. Forms a signaling complex with EPHA1, PTK2B AND PI3-
CC       KINASE; upon activation by EFNA1 which may regulate T-lymphocyte
CC       migration. Associates with ZAP70 and RHOH; these interactions
CC       allow LCK-mediated RHOH and CD3 subunit phosphorylation in the
CC       presence of functional ZAP70. Interacts with UNC119; this
CC       interaction plays a crucial role in activation of LCK. Interacts
CC       with CEACAM1 (via cytoplasmic domain); mediates CEACAM1
CC       phosphorylation resulting in PTPN6 recruitment that
CC       dephosphorylates TCR stimulation-induced CD247 and ZAP70
CC       (PubMed:18424730). {ECO:0000269|PubMed:12837766,
CC       ECO:0000269|PubMed:14610044, ECO:0000269|PubMed:14610046,
CC       ECO:0000269|PubMed:14757743, ECO:0000269|PubMed:17634955,
CC       ECO:0000269|PubMed:18424730, ECO:0000269|PubMed:23946459,
CC       ECO:0000269|PubMed:7504174, ECO:0000269|PubMed:7852312,
CC       ECO:0000269|PubMed:8618896, ECO:0000269|PubMed:8794306,
CC       ECO:0000269|PubMed:9178760}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-1348, EBI-1348;
CC       P22575:- (xeno); NbExp=7; IntAct=EBI-1348, EBI-866709;
CC       Q9YJQ8:- (xeno); NbExp=2; IntAct=EBI-1348, EBI-7709835;
CC       Q13444:ADAM15; NbExp=3; IntAct=EBI-1348, EBI-77818;
CC       P10275:AR; NbExp=7; IntAct=EBI-1348, EBI-608057;
CC       P20749:BCL3; NbExp=3; IntAct=EBI-1348, EBI-958997;
CC       P01730:CD4; NbExp=2; IntAct=EBI-1348, EBI-353826;
CC       Q5VV42:CDKAL1; NbExp=3; IntAct=EBI-1348, EBI-10194801;
CC       Q13480:GAB1; NbExp=10; IntAct=EBI-1348, EBI-517684;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-1348, EBI-352572;
CC       Q07666:KHDRBS1; NbExp=5; IntAct=EBI-1348, EBI-1364;
CC       P10721:KIT; NbExp=8; IntAct=EBI-1348, EBI-1379503;
CC       O43561:LAT; NbExp=2; IntAct=EBI-1348, EBI-1222766;
CC       Q9BRK4:LZTS2; NbExp=3; IntAct=EBI-1348, EBI-741037;
CC       Q9H204:MED28; NbExp=4; IntAct=EBI-1348, EBI-514199;
CC       P08581:MET; NbExp=3; IntAct=EBI-1348, EBI-1039152;
CC       P04150:NR3C1; NbExp=3; IntAct=EBI-1348, EBI-493507;
CC       Q04759:PRKCQ; NbExp=2; IntAct=EBI-1348, EBI-374762;
CC       Q9Y2R2:PTPN22; NbExp=6; IntAct=EBI-1348, EBI-1211241;
CC       P29350:PTPN6; NbExp=5; IntAct=EBI-1348, EBI-78260;
CC       P08575:PTPRC; NbExp=7; IntAct=EBI-1348, EBI-1341;
CC       Q9NP31:SH2D2A; NbExp=12; IntAct=EBI-1348, EBI-490630;
CC       P43405:SYK; NbExp=7; IntAct=EBI-1348, EBI-78302;
CC       P0CG48:UBC; NbExp=2; IntAct=EBI-1348, EBI-3390054;
CC       P43403:ZAP70; NbExp=2; IntAct=EBI-1348, EBI-1211276;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12218089}.
CC       Cell membrane {ECO:0000269|PubMed:12218089}; Lipid-anchor
CC       {ECO:0000269|PubMed:12218089}; Cytoplasmic side
CC       {ECO:0000269|PubMed:12218089}. Note=Present in lipid rafts in an
CC       inactive form.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Long;
CC         IsoId=P06239-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P06239-2; Sequence=VSP_005000, VSP_005001;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P06239-3; Sequence=VSP_016049;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed specifically in lymphoid cells.
CC   -!- DOMAIN: The SH2 domain mediates interaction with SQSTM1.
CC       Interaction is regulated by Ser-59 phosphorylation.
CC   -!- PTM: Autophosphorylated on Tyr-394, increasing enzymatic activity,
CC       this site is dephosphorylated by PTN22. Phosphorylated on Tyr-505
CC       by CSK, decreasing activity. Dephosphorylated by PTPRC/CD45.
CC       Dephosphorylation at Tyr-394 by PTPN2 negatively regulates T-cell
CC       receptor signaling. {ECO:0000269|PubMed:1639064,
CC       ECO:0000269|PubMed:22080863, ECO:0000269|PubMed:8139546,
CC       ECO:0000269|PubMed:8631775}.
CC   -!- PTM: Myristoylation is required prior to palmitoylation.
CC       {ECO:0000250}.
CC   -!- PTM: Palmitoylation regulates subcellular location. {ECO:0000250}.
CC   -!- MASS SPECTROMETRY: Mass=57869.42; Method=MALDI; Range=2-509;
CC       Evidence={ECO:0000269|PubMed:11840567};
CC   -!- DISEASE: Note=A chromosomal aberration involving LCK is found in
CC       leukemias. Translocation t(1;7)(p34;q34) with TCRB.
CC   -!- DISEASE: Immunodeficiency 22 (IMD22) [MIM:615758]: A primary
CC       immunodeficiency characterized by T-cell dysfunction. Affected
CC       individuals present with lymphopenia, recurrent infections, severe
CC       diarrhea, and failure to thrive. {ECO:0000269|PubMed:22985903}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAI22320.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=CAI22321.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LCKID14ch1p34.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Lck entry;
CC       URL="https://en.wikipedia.org/wiki/Lck";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05027; CAA28691.1; -; mRNA.
DR   EMBL; X13529; CAA31884.1; -; mRNA.
DR   EMBL; M36881; AAA59502.1; -; mRNA.
DR   EMBL; X14055; CAA32211.1; -; Genomic_DNA.
DR   EMBL; X14053; CAA32211.1; JOINED; Genomic_DNA.
DR   EMBL; X14054; CAA32211.1; JOINED; Genomic_DNA.
DR   EMBL; U07236; AAA18225.1; -; mRNA.
DR   EMBL; U23852; AAC50287.1; -; mRNA.
DR   EMBL; BN000073; CAD55807.1; -; Genomic_DNA.
DR   EMBL; AL121991; CAI22320.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AL121991; CAI22321.1; ALT_INIT; Genomic_DNA.
DR   EMBL; CH471059; EAX07543.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07546.1; -; Genomic_DNA.
DR   EMBL; BC013200; AAH13200.1; -; mRNA.
DR   EMBL; M21510; AAA59501.1; ALT_TERM; Genomic_DNA.
DR   EMBL; M26692; AAA59503.1; -; Genomic_DNA.
DR   EMBL; AF228313; AAF34794.1; -; mRNA.
DR   EMBL; X06369; CAA29667.1; -; mRNA.
DR   EMBL; X04476; CAA28165.1; -; mRNA.
DR   CCDS; CCDS359.1; -. [P06239-1]
DR   PIR; JQ0152; OKHULK.
DR   RefSeq; NP_001036236.1; NM_001042771.2. [P06239-1]
DR   RefSeq; NP_005347.3; NM_005356.4. [P06239-1]
DR   UniGene; Hs.470627; -.
DR   PDB; 1BHF; X-ray; 1.80 A; A=119-226.
DR   PDB; 1BHH; X-ray; 1.90 A; A=119-226, B=124-226.
DR   PDB; 1CWD; X-ray; 2.25 A; L=127-222.
DR   PDB; 1CWE; X-ray; 2.30 A; A/C=127-222.
DR   PDB; 1FBZ; X-ray; 2.40 A; A/B=123-226.
DR   PDB; 1H92; NMR; -; A=59-120.
DR   PDB; 1IJR; X-ray; 2.20 A; A=124-226.
DR   PDB; 1KIK; NMR; -; A=64-120.
DR   PDB; 1LCJ; X-ray; 1.80 A; A=119-226.
DR   PDB; 1LCK; X-ray; 2.50 A; A=53-226, B=502-509.
DR   PDB; 1LKK; X-ray; 1.00 A; A=122-226.
DR   PDB; 1LKL; X-ray; 1.80 A; A=123-226.
DR   PDB; 1Q68; NMR; -; B=7-35.
DR   PDB; 1Q69; NMR; -; B=7-35.
DR   PDB; 1QPC; X-ray; 1.60 A; A=231-509.
DR   PDB; 1QPD; X-ray; 2.00 A; A=231-509.
DR   PDB; 1QPE; X-ray; 2.00 A; A=231-509.
DR   PDB; 1QPJ; X-ray; 2.20 A; A=231-509.
DR   PDB; 1X27; X-ray; 2.70 A; A/B/C/D/E/F=64-226.
DR   PDB; 2IIM; X-ray; 1.00 A; A=59-119.
DR   PDB; 2OF2; X-ray; 2.00 A; A=231-501.
DR   PDB; 2OF4; X-ray; 2.70 A; A=231-501.
DR   PDB; 2OFU; X-ray; 2.00 A; A=229-501.
DR   PDB; 2OFV; X-ray; 2.00 A; A/B=232-498.
DR   PDB; 2OG8; X-ray; 2.30 A; A/B=237-499.
DR   PDB; 2PL0; X-ray; 2.80 A; A=225-509.
DR   PDB; 2ZM1; X-ray; 2.10 A; A=225-509.
DR   PDB; 2ZM4; X-ray; 2.70 A; A=225-509.
DR   PDB; 2ZYB; X-ray; 2.55 A; A=225-509.
DR   PDB; 3AC1; X-ray; 1.99 A; A=225-509.
DR   PDB; 3AC2; X-ray; 2.10 A; A=225-509.
DR   PDB; 3AC3; X-ray; 2.55 A; A=225-509.
DR   PDB; 3AC4; X-ray; 2.70 A; A=225-509.
DR   PDB; 3AC5; X-ray; 2.50 A; A=225-509.
DR   PDB; 3AC8; X-ray; 2.30 A; A=225-509.
DR   PDB; 3ACJ; X-ray; 2.20 A; A=225-509.
DR   PDB; 3ACK; X-ray; 2.60 A; A=225-509.
DR   PDB; 3AD4; X-ray; 2.20 A; A=225-509.
DR   PDB; 3AD5; X-ray; 2.00 A; A=225-509.
DR   PDB; 3AD6; X-ray; 2.15 A; A=225-509.
DR   PDB; 3B2W; X-ray; 2.30 A; A=226-502.
DR   PDB; 3BRH; X-ray; 2.20 A; C/D=391-397.
DR   PDB; 3BYM; X-ray; 2.00 A; A=230-501.
DR   PDB; 3BYO; X-ray; 2.00 A; A=231-501.
DR   PDB; 3BYS; X-ray; 2.20 A; A=225-501.
DR   PDB; 3BYU; X-ray; 2.30 A; A=225-501.
DR   PDB; 3KMM; X-ray; 2.80 A; A=229-509.
DR   PDB; 3KXZ; X-ray; 2.37 A; A=225-509.
DR   PDB; 3LCK; X-ray; 1.70 A; A=231-501.
DR   PDB; 3MPM; X-ray; 1.95 A; A=237-501.
DR   PDB; 4C3F; X-ray; 1.72 A; A=237-501.
DR   PDB; 4D8K; X-ray; 2.36 A; A=53-226.
DR   PDBsum; 1BHF; -.
DR   PDBsum; 1BHH; -.
DR   PDBsum; 1CWD; -.
DR   PDBsum; 1CWE; -.
DR   PDBsum; 1FBZ; -.
DR   PDBsum; 1H92; -.
DR   PDBsum; 1IJR; -.
DR   PDBsum; 1KIK; -.
DR   PDBsum; 1LCJ; -.
DR   PDBsum; 1LCK; -.
DR   PDBsum; 1LKK; -.
DR   PDBsum; 1LKL; -.
DR   PDBsum; 1Q68; -.
DR   PDBsum; 1Q69; -.
DR   PDBsum; 1QPC; -.
DR   PDBsum; 1QPD; -.
DR   PDBsum; 1QPE; -.
DR   PDBsum; 1QPJ; -.
DR   PDBsum; 1X27; -.
DR   PDBsum; 2IIM; -.
DR   PDBsum; 2OF2; -.
DR   PDBsum; 2OF4; -.
DR   PDBsum; 2OFU; -.
DR   PDBsum; 2OFV; -.
DR   PDBsum; 2OG8; -.
DR   PDBsum; 2PL0; -.
DR   PDBsum; 2ZM1; -.
DR   PDBsum; 2ZM4; -.
DR   PDBsum; 2ZYB; -.
DR   PDBsum; 3AC1; -.
DR   PDBsum; 3AC2; -.
DR   PDBsum; 3AC3; -.
DR   PDBsum; 3AC4; -.
DR   PDBsum; 3AC5; -.
DR   PDBsum; 3AC8; -.
DR   PDBsum; 3ACJ; -.
DR   PDBsum; 3ACK; -.
DR   PDBsum; 3AD4; -.
DR   PDBsum; 3AD5; -.
DR   PDBsum; 3AD6; -.
DR   PDBsum; 3B2W; -.
DR   PDBsum; 3BRH; -.
DR   PDBsum; 3BYM; -.
DR   PDBsum; 3BYO; -.
DR   PDBsum; 3BYS; -.
DR   PDBsum; 3BYU; -.
DR   PDBsum; 3KMM; -.
DR   PDBsum; 3KXZ; -.
DR   PDBsum; 3LCK; -.
DR   PDBsum; 3MPM; -.
DR   PDBsum; 4C3F; -.
DR   PDBsum; 4D8K; -.
DR   ProteinModelPortal; P06239; -.
DR   SMR; P06239; -.
DR   BioGrid; 110124; 89.
DR   DIP; DIP-553N; -.
DR   IntAct; P06239; 73.
DR   MINT; MINT-110378; -.
DR   STRING; 9606.ENSP00000337825; -.
DR   BindingDB; P06239; -.
DR   ChEMBL; CHEMBL258; -.
DR   DrugBank; DB06925; 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB02010; Staurosporine.
DR   GuidetoPHARMACOLOGY; 2053; -.
DR   iPTMnet; P06239; -.
DR   PhosphoSitePlus; P06239; -.
DR   SwissPalm; P06239; -.
DR   BioMuta; LCK; -.
DR   DMDM; 125474; -.
DR   EPD; P06239; -.
DR   MaxQB; P06239; -.
DR   PaxDb; P06239; -.
DR   PeptideAtlas; P06239; -.
DR   PRIDE; P06239; -.
DR   DNASU; 3932; -.
DR   Ensembl; ENST00000333070; ENSP00000328213; ENSG00000182866. [P06239-3]
DR   Ensembl; ENST00000336890; ENSP00000337825; ENSG00000182866. [P06239-1]
DR   Ensembl; ENST00000619559; ENSP00000477713; ENSG00000182866. [P06239-1]
DR   GeneID; 3932; -.
DR   KEGG; hsa:3932; -.
DR   UCSC; uc001bux.3; human. [P06239-1]
DR   CTD; 3932; -.
DR   DisGeNET; 3932; -.
DR   GeneCards; LCK; -.
DR   H-InvDB; HIX0019954; -.
DR   HGNC; HGNC:6524; LCK.
DR   HPA; CAB003816; -.
DR   HPA; HPA003494; -.
DR   MalaCards; LCK; -.
DR   MIM; 153390; gene.
DR   MIM; 615758; phenotype.
DR   neXtProt; NX_P06239; -.
DR   OpenTargets; ENSG00000182866; -.
DR   Orphanet; 280142; Severe combined immunodeficiency due to LCK deficiency.
DR   PharmGKB; PA30307; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P06239; -.
DR   KO; K05856; -.
DR   OMA; HTKVAIK; -.
DR   OrthoDB; EOG091G0D46; -.
DR   PhylomeDB; P06239; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-164944; Nef and signal transduction.
DR   Reactome; R-HSA-167590; Nef Mediated CD4 Down-regulation.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   Reactome; R-HSA-202430; Translocation of ZAP-70 to Immunological synapse.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-389356; CD28 co-stimulation.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-389948; PD-1 signaling.
DR   Reactome; R-HSA-451927; Interleukin-2 signaling.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   SignaLink; P06239; -.
DR   SIGNOR; P06239; -.
DR   ChiTaRS; LCK; human.
DR   EvolutionaryTrace; P06239; -.
DR   GeneWiki; Lck; -.
DR   GenomeRNAi; 3932; -.
DR   PRO; PR:P06239; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000182866; -.
DR   CleanEx; HS_LCK; -.
DR   ExpressionAtlas; P06239; baseline and differential.
DR   Genevisible; P06239; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0001772; C:immunological synapse; IDA:MGI.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0000242; C:pericentriolar material; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0051117; F:ATPase binding; IPI:UniProtKB.
DR   GO; GO:0042609; F:CD4 receptor binding; IPI:UniProtKB.
DR   GO; GO:0042610; F:CD8 receptor binding; IPI:UniProtKB.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0001784; F:phosphotyrosine binding; IPI:CAFA.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0042608; F:T cell receptor binding; IPI:CAFA.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0006882; P:cellular zinc ion homeostasis; IEP:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; NAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IMP:CAFA.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0050870; P:positive regulation of T cell activation; IDA:UniProtKB.
DR   GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0050690; P:regulation of defense response to virus by virus; TAS:Reactome.
DR   GO; GO:0051249; P:regulation of lymphocyte activation; NAS:UniProtKB.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; ISS:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0030217; P:T cell differentiation; IMP:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Complete proteome; Cytoplasm;
KW   Disease mutation; Host-virus interaction; Kinase; Lipoprotein;
KW   Membrane; Myristate; Nucleotide-binding; Palmitate; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; SH2 domain;
KW   SH3 domain; Transferase; Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    509       Tyrosine-protein kinase Lck.
FT                                /FTId=PRO_0000088124.
FT   DOMAIN       61    121       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      127    224       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      245    498       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     251    259       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        2     72       Interactions with CD4 and CD8.
FT                                {ECO:0000250}.
FT   REGION      154    242       Interaction with PTPRH.
FT                                {ECO:0000269|PubMed:12837766}.
FT   ACT_SITE    364    364       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     273    273       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     102    102       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     159    159       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     162    162       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     192    192       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P06240}.
FT   MOD_RES     194    194       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     394    394       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8139546}.
FT   MOD_RES     505    505       Phosphotyrosine; by CSK.
FT                                {ECO:0000244|PubMed:15592455,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000269|PubMed:1639064,
FT                                ECO:0000269|PubMed:8139546,
FT                                ECO:0000269|PubMed:8631775}.
FT   LIPID         2      2       N-myristoyl glycine. {ECO:0000250}.
FT   LIPID         3      3       S-palmitoyl cysteine. {ECO:0000250}.
FT   LIPID         5      5       S-palmitoyl cysteine. {ECO:0000250}.
FT   VAR_SEQ     321    321       N -> NDTLLDSQLEEKGLGASPWGNLGQQLLLLPT (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_016049.
FT   VAR_SEQ     348    363       IAEGMAFIEERNYIHR -> VRRLGRGAGQGNRPVT (in
FT                                isoform Short).
FT                                {ECO:0000303|PubMed:7495859}.
FT                                /FTId=VSP_005000.
FT   VAR_SEQ     364    509       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:7495859}.
FT                                /FTId=VSP_005001.
FT   VARIANT      28     28       V -> L (found in leukemia).
FT                                {ECO:0000269|PubMed:8139546}.
FT                                /FTId=VAR_013463.
FT   VARIANT     201    201       G -> S (in dbSNP:rs11567841).
FT                                /FTId=VAR_051697.
FT   VARIANT     232    232       P -> PQKP (in leukemia).
FT                                /FTId=VAR_013464.
FT   VARIANT     341    341       L -> P (in IMD22; dbSNP:rs587777335).
FT                                {ECO:0000269|PubMed:22985903}.
FT                                /FTId=VAR_071291.
FT   VARIANT     353    353       A -> V (found in leukemia).
FT                                {ECO:0000269|PubMed:8139546}.
FT                                /FTId=VAR_013465.
FT   VARIANT     447    447       P -> L (found in leukemia).
FT                                {ECO:0000269|PubMed:8139546}.
FT                                /FTId=VAR_013466.
FT   MUTAGEN      59     59       S->E: Allows interaction with SQSTM1.
FT                                {ECO:0000269|PubMed:8618896}.
FT   MUTAGEN     154    154       R->K: No effect on interaction with
FT                                SQSTM1. {ECO:0000269|PubMed:8618896}.
FT   CONFLICT     29     29       P -> R (in Ref. 2; AAA59502).
FT                                {ECO:0000305}.
FT   CONFLICT     35     35       T -> R (in Ref. 2; AAA59502).
FT                                {ECO:0000305}.
FT   CONFLICT     87     87       Q -> P (in Ref. 2; CAA31884/AAA59502).
FT                                {ECO:0000305}.
FT   CONFLICT    206    211       VRHYTN -> ASAITPI (in Ref. 1; CAA28691).
FT                                {ECO:0000305}.
FT   CONFLICT    254    254       G -> A (in Ref. 2; AAA59502).
FT                                {ECO:0000305}.
FT   CONFLICT    258    267       EVWMGYYNGH -> RCGWGTTTGT (in Ref. 1;
FT                                CAA28691). {ECO:0000305}.
FT   CONFLICT    282    286       PDAFL -> AGRLP (in Ref. 1; CAA28691).
FT                                {ECO:0000305}.
FT   CONFLICT    375    375       T -> A (in Ref. 14; CAA28165).
FT                                {ECO:0000305}.
FT   CONFLICT    472    472       L -> H (in Ref. 13; CAA29667).
FT                                {ECO:0000305}.
FT   CONFLICT    504    509       QYQPQP -> STA (in Ref. 1; CAA28691).
FT                                {ECO:0000305}.
FT   HELIX        12     15       {ECO:0000244|PDB:1Q68}.
FT   STRAND       21     23       {ECO:0000244|PDB:1Q68}.
FT   STRAND       24     27       {ECO:0000244|PDB:1Q69}.
FT   TURN         60     63       {ECO:0000244|PDB:2IIM}.
FT   STRAND       65     70       {ECO:0000244|PDB:2IIM}.
FT   STRAND       76     79       {ECO:0000244|PDB:4D8K}.
FT   STRAND       87     92       {ECO:0000244|PDB:2IIM}.
FT   STRAND       95    102       {ECO:0000244|PDB:2IIM}.
FT   TURN        103    105       {ECO:0000244|PDB:2IIM}.
FT   STRAND      108    112       {ECO:0000244|PDB:2IIM}.
FT   HELIX       113    115       {ECO:0000244|PDB:2IIM}.
FT   STRAND      116    118       {ECO:0000244|PDB:2IIM}.
FT   STRAND      128    131       {ECO:0000244|PDB:1CWD}.
FT   HELIX       134    141       {ECO:0000244|PDB:1LKK}.
FT   STRAND      151    155       {ECO:0000244|PDB:1LKK}.
FT   STRAND      157    159       {ECO:0000244|PDB:1LKK}.
FT   STRAND      163    171       {ECO:0000244|PDB:1LKK}.
FT   TURN        172    174       {ECO:0000244|PDB:1LKK}.
FT   STRAND      175    185       {ECO:0000244|PDB:1LKK}.
FT   TURN        187    189       {ECO:0000244|PDB:1LCJ}.
FT   STRAND      191    194       {ECO:0000244|PDB:1LKK}.
FT   STRAND      199    201       {ECO:0000244|PDB:1LKK}.
FT   HELIX       202    211       {ECO:0000244|PDB:1LKK}.
FT   STRAND      216    218       {ECO:0000244|PDB:1LKK}.
FT   TURN        233    235       {ECO:0000244|PDB:1QPC}.
FT   STRAND      237    239       {ECO:0000244|PDB:1QPE}.
FT   HELIX       242    244       {ECO:0000244|PDB:1QPC}.
FT   STRAND      245    254       {ECO:0000244|PDB:1QPC}.
FT   STRAND      257    264       {ECO:0000244|PDB:1QPC}.
FT   TURN        265    267       {ECO:0000244|PDB:1QPC}.
FT   STRAND      268    275       {ECO:0000244|PDB:1QPC}.
FT   TURN        277    279       {ECO:0000244|PDB:1QPD}.
FT   HELIX       282    294       {ECO:0000244|PDB:1QPC}.
FT   STRAND      303    307       {ECO:0000244|PDB:1QPC}.
FT   STRAND      309    311       {ECO:0000244|PDB:1QPC}.
FT   STRAND      313    317       {ECO:0000244|PDB:1QPC}.
FT   HELIX       324    327       {ECO:0000244|PDB:1QPC}.
FT   HELIX       331    334       {ECO:0000244|PDB:1QPC}.
FT   HELIX       338    357       {ECO:0000244|PDB:1QPC}.
FT   HELIX       367    369       {ECO:0000244|PDB:1QPC}.
FT   STRAND      370    372       {ECO:0000244|PDB:1QPC}.
FT   STRAND      378    380       {ECO:0000244|PDB:1QPC}.
FT   HELIX       383    385       {ECO:0000244|PDB:1QPE}.
FT   HELIX       386    389       {ECO:0000244|PDB:3B2W}.
FT   STRAND      390    392       {ECO:0000244|PDB:1QPC}.
FT   STRAND      393    395       {ECO:0000244|PDB:4C3F}.
FT   TURN        404    406       {ECO:0000244|PDB:1QPC}.
FT   HELIX       409    414       {ECO:0000244|PDB:1QPC}.
FT   HELIX       419    434       {ECO:0000244|PDB:1QPC}.
FT   TURN        435    437       {ECO:0000244|PDB:1QPC}.
FT   HELIX       446    454       {ECO:0000244|PDB:1QPC}.
FT   HELIX       467    476       {ECO:0000244|PDB:1QPC}.
FT   HELIX       481    483       {ECO:0000244|PDB:1QPC}.
FT   HELIX       487    500       {ECO:0000244|PDB:1QPC}.
SQ   SEQUENCE   509 AA;  58001 MW;  44BFF0D43FFB420D CRC64;
     MGCGCSSHPE DDWMENIDVC ENCHYPIVPL DGKGTLLIRN GSEVRDPLVT YEGSNPPASP
     LQDNLVIALH SYEPSHDGDL GFEKGEQLRI LEQSGEWWKA QSLTTGQEGF IPFNFVAKAN
     SLEPEPWFFK NLSRKDAERQ LLAPGNTHGS FLIRESESTA GSFSLSVRDF DQNQGEVVKH
     YKIRNLDNGG FYISPRITFP GLHELVRHYT NASDGLCTRL SRPCQTQKPQ KPWWEDEWEV
     PRETLKLVER LGAGQFGEVW MGYYNGHTKV AVKSLKQGSM SPDAFLAEAN LMKQLQHQRL
     VRLYAVVTQE PIYIITEYME NGSLVDFLKT PSGIKLTINK LLDMAAQIAE GMAFIEERNY
     IHRDLRAANI LVSDTLSCKI ADFGLARLIE DNEYTAREGA KFPIKWTAPE AINYGTFTIK
     SDVWSFGILL TEIVTHGRIP YPGMTNPEVI QNLERGYRMV RPDNCPEELY QLMRLCWKER
     PEDRPTFDYL RSVLEDFFTA TEGQYQPQP
//
